Co-Diagnostics, Inc. (CODX) investor relations documents from the company's IR site: 1 presentation, 5 press releases; latest deck 2026-05-15. Read in-app with summaries. First-party data.
Investor Deck — Co-Diagnostics, Inc. is a molecular diagnostics company developing the Co-Dx PCR Pro platform, currently pending FDA/regulatory review.
| Published | Type | Document |
|---|---|---|
| 2026-08-18 | Press release | Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event |
| 2026-07-30 | Press release | Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast |
| 2026-07-28 | Press release | Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies |
| 2026-07-01 | Press release | Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory P |
| 2026-06-18 | Press release | Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line |
| 2026-05-15 | Presentation | Investor Deck |
CODX overview · CODX earnings · CODX financials · CODX KPIs · CODX ownership · CODX peers · CODX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.